ArticleFrontiers in pharmacology2026
Observational real-world analysis of dose-dependent effects of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This study represents a secondary analysis of data collected during a real-world, longitudinal observational study of adult U.S. participants using a kratom product composed of proprietary full spectrum leaf extract, designed to mimic a traditional kratom tea. Phytochemical equivalence to traditional preparations was established by comparing the alkaloid profile and presence of plant phenylpropanoids. Participants completed daily structured surveys over a 21-day period. Linear mixed-effects models were used to evaluate within-subject changes across baseline, week 1, and week 2 periods. Results: Chemical analyses confirmed that the presence and relative ratios of alkaloids were comparable to those found in traditional kratom tea, supporting the extract as a standardized representation of traditional decoctions. At the 20 mg mitragynine-equivalent dose, participants showed statistically significant improvements in focus, problem solving, mental clarity, and energy (p < 0.05). Conclusion: A kratom product formulated to be dose-aligned with a traditional kratom tea serving is associated with stimulant-like benefits, increasing energy and focus. This effects profile implies that the pharmacological activity at this dose likely reflects non-opioid receptor mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.